

Melanoma Pathways: Metastatic Melanoma

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

Pathology: _____ Stage: _____

Line of Therapy: Adjuvant/Post-Op 1st Line 2nd Line
 3rd Line 3rd Line+ **ECOG Performance Status:** _____ **ICD-10 Code:** _____

Biomarkers/Characteristics: (Select all that apply)

BRAF⁺ status: V600E Mutation positive V600K Mutation positive Wild Type (no mutation) Not Reported

c-kit status: Exon 11 Mutation Present Exon 9 Mutation Present No Mutation Not Reported

Stage IIIB/IIIC (Resected) | Adjuvant Therapy

Nivolumab (Opdivo)*

Metastatic Disease | First and Subsequent Lines of Therapy (1st Line+) | Any BRAF Status | ECOG PS: 0-2

Pembrolizumab (Keytruda)†

Metastatic Disease | First Line of Therapy (1st Line) | BRAF Mutated‡ | Symptomatic Disease | ECOG PS: 0-2

Vemurafenib (Zelboraf) and cobimetinib (Cotellic)

Metastatic Disease | Second and Subsequent Lines of Therapy (2nd Line+) | BRAF Mutated‡ | ECOG PS: 0-2

Vemurafenib (Zelboraf) and cobimetinib (Cotellic)

Metastatic Disease | Second and Subsequent Lines of Therapy (2nd Line+) | Any BRAF Status | ECOG PS: 0-2

Ipilimumab (Yervoy)

*Administered at a dose of 240 mg every 2 weeks or 480 mg every 4 weeks

†Administered at a dose of 2 mg/kg (up to a maximum of 200 mg).

‡BRAF mutations include V600E and V600K mutations.

Note: Pathway lists are solely for the purpose of eligibility for enhanced reimbursement and are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.